News

November 8, 2021

Cellphire Therapeutics Names Angie Howerton as Vice President of Finance, Controller and Treasurer

Ms. Howerton brings 25-years of progressive experience with a range of companies. Before joining Cellphire, she held leadership roles at ExeGi Pharma, Thermo Fisher Scientific, and MTI-GlobalStem.

May 28, 2021

Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients

Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company’s Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia. The study will evaluate the safety and efficacy of infusing multiple dose levels of Thrombosomes versus standard liquid stored platelets.

April 20, 2021

Cellphire Therapeutics Names Michael Gaffney as Company’s New CEO

Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately. Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire. He will also join the Company’s board.

April 5, 2021

Cellphire, Inc. Announces Rebrand to Cellphire Therapeutics, Inc.

Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today the company’s rebranding to Cellphire Therapeutics, Inc. The significant rebrand includes a new logo and website.

April 2, 2021

Cellphire Therapeutics Closes $15 Million Series A Funding Round Led by Simcah Management

Cellphire Therapeutics, Inc., the global leader in long-term stabilization and storage of platelets, announced today the close of a $15 million Series A financing round led by Simcah Management.

September 23, 2020

Cellphire President G. Michael Fitzpatrick Awarded Armed Services Program Lifetime Achievement Award

Cellphire, the global leader in long-term stabilization and storage of platelets, is proud to announce that the Armed Services Blood Program (ASBP) has awarded Cellphire President G. Michael Fitzpatrick, PhD, with the 2020 ASBP Lifetime Achievement Award for his service and significant contributions to ASBP and the warfighter.

June 3, 2020

Cellphire Subsidiary, BodeVet, Inc., Awarded $1.7 Million U.S. Army Contract

BodeVet, Inc., a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 2-year contract valued at $1.7 million to conduct a clinical trial in canine polytrauma patients at veterinary critical care hospitals.

May 18, 2020

Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients

Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to start a Phase 2 clinical trial of Thrombosomes in bleeding patients with thrombocytopenia.